Tatva Chintan Pharma Chem Second Quarter 2025 Earnings: Misses Expectations

Tatva Chintan Pharma Chem (NSE:TATVA) Second Quarter 2025 Results

Key Financial Results

• Revenue: ₹838.7m (down 13% from 2Q 2024).
• Net loss: ₹6.64m (down by 109% from ₹77.8m profit in 2Q 2024).
• ₹0.29 loss per share (down from ₹3.43 profit in 2Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tatva Chintan Pharma Chem Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 19%. Earnings per share (EPS) was also behind analyst expectations.

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India.

Performance of the Indian Chemicals industry.

The company's shares are down 7.6% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for Tatva Chintan Pharma Chem that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.